Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 762,656 shares of RXRX, which is worth approximately $4.88 Million. The most recent transaction as insider was on Oct 03, 2024, when has been sold 20,000 shares (Class A Common Stock) at a price of $6.08 per share, resulting in proceeds of $121,600. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 763K

0.52% 3M change

8.86% 12M change

Total Value Held $4.88 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 03 2024	SELL Open market or private sale	$121,600 $6.08 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock
Oct 03 2024	BUY Conversion of derivative security	-	20,000 Added 2.49%	782,656 Class A Common Stock
Oct 02 2024	SELL Open market or private sale	$123,200 $6.16 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock
Oct 02 2024	BUY Conversion of derivative security	-	20,000 Added 2.49%	782,656 Class A Common Stock
Sep 05 2024	SELL Open market or private sale	$122,800 $6.14 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock
Sep 05 2024	BUY Conversion of derivative security	-	20,000 Added 2.49%	782,656 Class A Common Stock
Sep 04 2024	SELL Open market or private sale	$120,800 $6.04 p/Share	20,000 Reduced 2.56%	762,656 Class A Common Stock
Sep 04 2024	BUY Conversion of derivative security	-	20,000 Added 2.49%	782,656 Class A Common Stock
Aug 30 2024	BUY Exercise of conversion of derivative security	$12,400 $2.48 p/Share	5,000 Added 0.65%	762,656 Class A Common Stock
Aug 29 2024	BUY Exercise of conversion of derivative security	$12,400 $2.48 p/Share	5,000 Added 0.66%	757,656 Class A Common Stock
Aug 28 2024	BUY Exercise of conversion of derivative security	$12,400 $2.48 p/Share	5,000 Added 0.66%	752,656 Class A Common Stock
Aug 27 2024	BUY Exercise of conversion of derivative security	$12,400 $2.48 p/Share	5,000 Added 0.66%	747,656 Class A Common Stock
Aug 26 2024	BUY Exercise of conversion of derivative security	$12,400 $2.48 p/Share	5,000 Added 0.67%	742,656 Class A Common Stock
Aug 23 2024	BUY Exercise of conversion of derivative security	$12,400 $2.48 p/Share	5,000 Added 0.67%	737,656 Class A Common Stock
Aug 15 2024	SELL Payment of exercise price or tax liability	$174,488 $6.69 p/Share	26,082 Reduced 3.44%	732,656 Class A Common Stock
Aug 08 2024	SELL Open market or private sale	$130,000 $6.5 p/Share	20,000 Reduced 2.57%	758,738 Class A Common Stock
Aug 08 2024	BUY Conversion of derivative security	-	20,000 Added 2.5%	778,738 Class A Common Stock
Aug 07 2024	SELL Open market or private sale	$213,000 $7.1 p/Share	30,000 Reduced 3.8%	758,738 Class A Common Stock
Aug 07 2024	BUY Conversion of derivative security	-	30,000 Added 3.66%	788,738 Class A Common Stock
Jul 11 2024	SELL Open market or private sale	$373,500 $7.47 p/Share	50,000 Reduced 6.18%	758,738 Class A Common Stock
Jul 11 2024	BUY Conversion of derivative security	-	50,000 Added 5.82%	808,738 Class A Common Stock
Jul 10 2024	SELL Bona fide gift	-	25,000 Reduced 3.19%	758,738 Class A Common Stock
Jul 10 2024	SELL Open market or private sale	$374,000 $7.48 p/Share	50,000 Reduced 6.18%	758,738 Class A Common Stock
Jul 10 2024	BUY Conversion of derivative security	-	50,000 Added 5.82%	808,738 Class A Common Stock
Jun 06 2024	SELL Open market or private sale	$450,000 $9.0 p/Share	50,000 Reduced 6.59%	708,738 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account